By Maureen Martino Eli Lilly and Boehringer Ingelheim have teamed on research and commercialization of four drugs–two from Lilly and two from Boehringer–for the treatment of diabetes. And the developers could expand their pact to include work on an anti-TGF-beta monoclonal antibody. The deal covers Boehringer two oral diabetes agents–linagliptin (under regulatory review in the U.S., …
By John Carroll Germany’s Boehringer Ingelheim is planning to bring out the check book as it scours everything from early-stage biotechs to developers with marketed products for “targeted acquisitions” that can help the pharma company make up for the revenue being lost to new generic competitors. Boehringer appears eager to build on recent deals to …
By John Carroll Corporate venture arms have become all the rage in the pharma world, and now Boehringer Ingelheim is weighing in with its own €100 million fund. The Boehringer Ingelheim Venture Fund–BIVF–plans to invest in biotech and start-up companies, with its first deals planned for later in the year. “Our investments will extend beyond …
